Geron Corporation has reported its financial results for the third quarter of 2026, showcasing a robust performance that highlights the growing demand for its lead product, RYTELO (imetelstat). The company achieved $60.1 million in net product revenue for RYTELO, marking a 5% increase from the previous quarter. This growth reinforces Geron's confidence in the commercial potential of RYTELO, particularly within the lower-risk myelodysplastic syndromes (LR-MDS) market.

In a press release dated November 4, 2026, Geron emphasized its commitment to expanding access to RYTELO in targeted European markets. The company has initiated a gated commercial launch, with availability expected in Germany by the end of the year and further expansion planned for France in 2027. This strategic move aims to reach more patients and enhance the company's market presence in the pharmaceutical sector.

Geron Corporation, based in Foster City, California, operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol GERN. Geron focuses on developing therapies for patients with blood cancers, positioning itself as a key player in the biopharmaceutical industry.

The recent filing reveals that Geron ended the third quarter with a strong financial position, reporting cash, cash equivalents, restricted cash, and marketable securities totaling $339 million. This financial stability provides the company with the resources needed to support its growth initiatives and further develop its product offerings.

In addition to its financial results, Geron highlighted several recent business achievements. The company reported a 10% increase in RYTELO demand compared to the second quarter of 2026, along with an increase in ordering accounts by approximately 8%, bringing the total to around 1,700 accounts. These metrics indicate a positive trend in market acceptance and utilization of RYTELO.

As part of its ongoing efforts to establish itself as a leader in hematology, Geron also participated in several significant medical conferences. The company exhibited three posters at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, showcasing real-world evidence of imetelstat's effectiveness in treating LR-MDS. Furthermore, Geron delivered an oral presentation at the 2026 Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology, discussing the potential benefits of imetelstat treatment.

Looking ahead, Geron aims to leverage its strong financial position and recent business momentum to expand its market reach and continue driving growth. The company has reiterated its 2026 RYTELO net product revenue guidance at the mid-to-high end of the $220 million to $240 million range, while also lowering its total operating expenses forecast to between $220 million and $230 million.

The filing does not specify what happens next, but the company is expected to host a conference call and webcast on the same day as the release to discuss these results in more detail.